IL17A and chronic obstructive pulmonary disease: In this study, we found in the mouse models of COPD, despite decreased neutrophil recruitment after treatment with IL-17A–neutralizing antibody, no increased bacterial burden was observed in the lungs, suggesting IL-17A was not critical in the clearance of P. aeruginosa during AECOPD.